Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Increased Cardiovascular Risk With Lorlatinib in Patients With ALK-Mutated Lung Cancer: A Real-World Comparative Study.

Journal of the American Heart Association - 16 Dec 2025

Lin Chien-Yu, Su Po-Lan, Kuo Chin-Wei, Tsai I-Lin, Liu Ting-Hui, Yang Jen, Lin Chien-Chung, Lin Sheng-Hsiang

Abstract excerpt

BACKGROUND: The discovery of driver mutations has transformed advanced non-small cell lung cancer treatment, with ALK (anaplastic lymphoma kinase)-rearranged patients achieving longest overall survival. However, the risk of cancer therapy-related cardiovascular diseases (CTRCVDs) is underrecognized, particularly comparing second-generation ALK-tyrosine kinase inhibitors alectinib and brigatinib to the...

Read the complete abstract on PubMed

Topics

Humans
Male
Female
Lung Neoplasms
Anaplastic Lymphoma Kinase
Retrospective Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Middle Aged

Aminopyridines

Aged

Mutation

Lactams

Carcinoma, Non-Small-Cell Lung

Protein Kinase Inhibitors

Lactams, Macrocyclic

Cardiovascular Diseases

Risk Assessment

Incidence

Organophosphorus Compounds

Source

Open in PubMed Open full text

Identifiers

PMID: 41378495
DOI: 10.1161/JAHA.125.043620
PMCID: PMC12826940

Genes

ALK
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Increased Cardiovascular Risk With Lorlatinib in Patients With ALK-Mutated Lung Cancer: A Real-World Comparative Study.PMID 41378495Read ↗

Cardiotoxicity Associated with Targeted Therapies in Lung Cancer: A Retrospective Cohort Study of 2,427 Patients with FAERS Pharmacovigilance ValidationSemantic proximity Read ↗

The Association Between Thromboembolic Events and ALK, ROS1, RET Rearrangements or EGFR Mutations in Patients With Advanced Lung Adenocarcinoma: A Retrospective Cohort Study.Semantic proximity Read ↗

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Pulmonary Embolism And Bradycardia in a NSCLC Patient Treated With Crizotinib For a Rare Mutation: A Case ReportSemantic proximity Read ↗

A user’s guide to lorlatinibSemantic proximity Read ↗

Pulmonary embolism and bradycardia in a NSCLC patient treated with crizotinib for a rare mutation.Semantic proximity Read ↗

Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis.Semantic proximity Read ↗

Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study.Semantic proximity Read ↗

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.Semantic proximity Read ↗

Cardiotoxicity from Bruton tyrosine kinase inhibitors (BTKi) – an analysis of an administrative health claims databaseSemantic proximity Read ↗

Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer.Semantic proximity Read ↗

Lung cancer and Risk of Cardiovascular MortalitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.